BCL2L11 and chronic myelogenous leukemia, BCR-ABL1 positive: To determine if SB939 had activity against primary CML cells, we treated cells with or without the BIM deletion polymorphism with SB939, either alone or in combination with IM, for 72 hours (Fig 4).